Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Gilead Sciences (GILD) Q1 2020 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Thursday said its first-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction. The company did not provide guidance for fiscal 2020, due to the coronavirus-driven uncertainty.
First-quarter adjusted earnings increased to $1.68 per share from $1.67 per share a year earlier. Analysts were looking for a smaller bottom-line number.
Net income, on an unadjusted basis, came in at $1.55 billion or $1.22 per share, compared to $1.98 billion or $1.54 per share in the prior-year period. The improvement primarily reflects favorable tax effects and gains from equity securities.
Revenues moved up 5% year-over-year to $5.55 billion and exceeded the market’s prediction. The company’s stock closed Thursday’s regular trading higher, hut slipped into the negative territory during the after-hours session.
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with